Opthea is a biopharmaceutical company. Co. develops and commercializes therapies mainly for eye disease. Co.'s primary asset, OPT-302, is a soluble form of Vascular Endothelial Growth Factors (VEGF) Receptor-3 in clinical development as a therapy for wet (neovascular) age-related macular degeneration (Wet AMD) and diabetic macular edema (DME). Wet AMD and DME are the main causes of blindness in the elderly and diabetic populations respectively. Co.'s development activities are based on an intellectual property portfolio covering primary targets (VEGF-C, VEGF-D and VEGF Receptor-3) for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. We show 1 historical shares outstanding datapoints in our OPT shares outstanding history coverage, used to compute OPT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing OPT market cap history over the course of time is important for investors
interested in comparing OPT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of OPT versus a peer is one thing; comparing
OPT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like OPT can fluctuate over the course of history.
With this page we aim to empower investors researching OPT by allowing them to research the OPT market cap history. |
Free OPT Email Alerts:
Video: The Importance of Market Cap
